小児臨床試験の世界市場

小児臨床試験の世界市場は2030年までに米国で242億米ドルに達する見込み

2024年に193億米ドルと推定される小児臨床試験の世界市場は、2024年から2030年にかけてCAGR 3.8%で成長し、2030年には242億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフェーズIは、CAGR 2.8%を記録し、分析期間終了までに99億米ドルに達すると予測されます。フェーズIIセグメントの成長率は、分析期間でCAGR 4.7%と推定されます。

米国市場は53億米ドルと推定、中国はCAGR6.8％で成長予測

米国の小児臨床試験市場は、2024年に53億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに48億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と2.9%と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界の小児臨床試験市場- 主要動向と促進要因まとめ

なぜ小児に特化した研究は医薬品開発においてもはやオプションではないのか？

小児臨床試験は、医薬品開発の周辺的な要素から、規制上および倫理上の必須事項へと移行しています。これは、小児には成人研究からの単なる外挿ではなく、明確な科学的評価が必要であるというコンセンサスの高まりを反映しています。歴史的に、小児患者に処方される医薬品の大部分は適応外であり、小児に特化した安全性と有効性のデータが欠如していたため、治療プロトコールにかなりのリスクと不確実性をもたらしていました。今日、米国FDAの小児研究公正法（PREA）、EUの小児規制、アジア太平洋地域の同様の取り組みなど、国際的な規制の枠組みは、新薬申請の一部として年齢に応じた研究を義務付けています。このシフトにより、がん、希少遺伝性疾患、神経、内分泌、感染症、呼吸器などの治療領域において、小児臨床試験が着実に増加しています。これらの臨床試験は、年齢相応の投与、発達に伴う薬物動態、製剤設計、倫理的同意、長期転帰モニタリングといった複雑な検討事項に対応する必要があり、専門的なプロトコールやインフラが必要となります。そのため、小児臨床試験の実施は、治験責任医師のトレーニング、小児に特化した臨床研究機関（CRO）、小児患者支援団体の関与などを必要とするニッチな専門分野となっています。大手製薬会社は、医薬品開発ライフサイクルの早い段階で小児中心の研究を統合するために、小児専門の卓越したセンターを設立しています。さらに、新生児スクリーニングや遺伝子検査による疾病の早期発見が世界的に増加する中、臨床試験デザインは、小児集団における急性および予防の両方の治験療法に対応できるように進化しています。小児科研究の制度化が進むことは、単に規制上の要請というだけでなく、年齢を包括したエビデンスに基づく医療への変革なのです。

臨床試験デザインと規制改革はどのように小児研究モデルを再構築しているのか？

臨床試験手法と規制戦略の進歩は、小児研究をより機敏で、正確で、倫理的に健全なものにする上で、変革的な役割を果たしています。従来の臨床試験モデルは、募集の課題、患者数の少なさ、実験的治療に小児を参加させることの倫理的敏感さなどの理由から、小児集団には適していないことが多いです。これに対し、規制当局やスポンサーは、より小規模で層別化されたコホートから意味のあるデータを抽出するために、適応試験デザイン、ベイズ統計、リアルワールドエビデンス（RWE）モデルを採用しています。小児臨床試験は、参加者とその家族の負担を軽減するために、遠隔医療、ウェアラブルセンサー、遠隔データ収集などを活用し、分散型やハイブリッド型の枠組みを取り入れることが増えています。このようなモデルは、患者集団が地理的に分散しており、国境を越えて参加登録を最大化しなければならない希少疾患研究において、特に有用であることが証明されつつあります。同時に、青少年から試験を開始し、徐々に低年齢の小児や乳幼児を組み入れる年齢ディスカレーション戦略も、安全性リスクの軽減や投与プロトコルの改良に役立っています。規制面では、小児適応を積極的に追及する企業に対し、迅速臨床試験（fast-track）指定、小児調査計画（PIPs）、市場独占権の延長などのインセンティブが当局から提供されるようになっています。倫理委員会はより合理化され、世界的に調和されつつあり、多施設臨床試験の迅速な承認が促進されています。さらに、e-consentのためのデジタルプラットフォームや小児にやさしい臨床試験教育資料は、親のためらいを克服し、十分な情報を得た上での参加を促進するのに役立っています。これらの技術革新は、単なる管理上の利便性ではなく、小児とその介護者のユニークなニーズを尊重しつつ、科学的厳密性を維持する、より効率的でスケーラブルかつコンプライアンスに優れた小児臨床試験を可能にしています。

なぜスポンサーとCROは小児臨床試験のインフラに積極的に投資しているのか？

スポンサーの関心が高まり、小児に特化したインフラ開発が急増しているためです。臨床研究機関（CRO）は、小児に特化したポートフォリオを拡大し、小児に特化した治験責任医師を採用し、小児専門のプロジェクト管理チームを結成して、小児に特化した臨床試験の複雑なロジスティクス、規制、治療上の要求に対応しています。主要なスポンサーは、小児病院や大学医療センター内の小児研究ハブや治験ネットワークに投資しており、質の高いデータと登録の効率性は、専門的な臨床施設へのアクセスに大きく依存していることを認識しています。特にインド、ブラジル、東南アジアなどの新興市場では、小児人口が多く、医療インフラが拡大しているため、未開拓の被験者募集の可能性があります。このような拡大は、治験実施施設の開発や能力開発イニシアチブを促進する政府やNGOによって支えられています。さらに、小児希少疾患の増加により、製薬会社、非営利財団、患者擁護団体が協力し、臨床試験プロトコール、自然歴データベース、レジストリを共同開発しています。ゲノムとバイオマーカーに基づく適格性基準の統合も、特に腫瘍学と神経学において患者選択を洗練させ、より的を絞った有意義な転帰を可能にしています。電子データ収集（EDC）、遠隔モニタリングプラットフォーム、デジタル患者参加ツールなどの技術的インフラは、リアルタイムの監視とコンプライアンスを強化しています。このような努力の積み重ねが、臨床試験業務の合理化、サイクルタイムの短縮、小児臨床試験のスケーラビリティの向上をもたらしています。このインフラ変革は長期的な戦略転換を反映したものであり、小児臨床試験を規制上の後回しではなく、将来の臨床開発パイプラインの中核的な柱として位置づけるものです。

小児臨床試験市場の成長はいくつかの要因によってもたらされる...

小児臨床試験市場の成長は、規制上の義務付け、治療法の革新、進化する試験実施モデルなど、いくつかの要因によってもたらされます。最も大きな要因の1つは、新薬や生物学的製剤の開発プログラムに小児集団を含めるよう規制当局が圧力を強めていることであり、スポンサーは製品ライフサイクルの早い段階で並行して小児計画を開始するよう促されています。同時に、小児に発症する疾患（特に腫瘍学、神経学、希少遺伝性疾患）を対象とした精密医療や遺伝子治療のパイプラインの拡大により、小児に特化したエンドポイントを用いた年齢層別臨床試験が必要となっています。エンドユースの面では、小児病院、小児科学術センター、世界の研究ネットワークが、小児バイオバンク、ゲノムスクリーニングツール、一元化された倫理審査機構など、治験準備インフラへの投資を進めており、治験のセットアップと実施を加速させています。小児用製剤科学の進歩も重要な成長要因の一つで、ミニ錠剤、溶解可能なフィルム、味覚マスキングされた液剤など、年齢に応じたデリバリーシステムを可能にし、臨床試験のアドヒアランスと安全性を支えています。さらに、デジタルトランスフォーメーションが重要な役割を果たしています。遠隔患者モニタリング、分散型臨床試験プラットフォーム、AIベースの患者マッチングにより、リクルート、リテンション、リアルタイムのデータ分析が改善されています。消費者の立場からは、保護者の意識の高まり、擁護団体の活動、小児研究に対する社会的信頼の高まりが、登録率と試験の透明性を高めています。また、スポンサーとヘルスケア提供者の間で、研究を日常診療と統合し、標準的な小児科診療の中で実臨床のエビデンスを作成できるようにするための連携が強まっています。バイオ製薬企業がパイプラインの差別化を図り、小児医療におけるアンメットニーズを満たそうとする中、臨床試験部門には資金が注入され、技術革新と戦略的優先順位付けが行われています。このようなダイナミクスの収束は、小児の医薬品開発のペースを加速させるだけでなく、より包括的でデータ主導型の、小児中心の世界の臨床研究エコシステムの基盤を築きつつあります。

セグメント

フェーズ（第I相、第II相、第III相、第IV相）、試験デザイン（治療研究、観察研究）、適応症（感染症、がん、自己免疫／炎症、呼吸器疾患、精神疾患、その他）

調査対象企業の例

• AbbVie Inc.
• Bristol-Myers Squibb Company
• Charles River Laboratories International Inc.
• Covance Inc.（now part of Labcorp）
• Eli Lilly and Company
• GlaxoSmithKline plc（GSK）
• ICON plc
• IQVIA Holdings Inc.
• Johnson & Johnson
• Medpace, Inc.
• Novartis AG
• Parexel International Corporation
• Pfizer Inc.
• PPD Inc.（Pharmaceutical Product Development）
• PRA Health Sciences（now part of ICON plc）
• Premier Research
• Sanofi S.A.
• Syneos Health Inc.
• Takeda Pharmaceutical Company Limited
• The Emmes Company, LLC

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Pediatric Clinical Trials Market to Reach US$24.2 Billion by 2030

The global market for Pediatric Clinical Trials estimated at US$19.3 Billion in the year 2024, is expected to reach US$24.2 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$9.9 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.3 Billion While China is Forecast to Grow at 6.8% CAGR

The Pediatric Clinical Trials market in the U.S. is estimated at US$5.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Pediatric Clinical Trials Market - Key Trends & Drivers Summarized

Why Is Pediatric-Specific Research No Longer Optional in the Drug Development Landscape?

Pediatric clinical trials have transitioned from a peripheral element of drug development to a regulatory and ethical imperative, reflecting a growing consensus that children require distinct scientific evaluation rather than mere extrapolation from adult studies. Historically, a significant portion of drugs prescribed to pediatric patients were off-label, lacking pediatric-specific safety and efficacy data, which introduced considerable risk and uncertainty into treatment protocols. Today, international regulatory frameworks such as the U.S. FDA’s Pediatric Research Equity Act (PREA), the EU Pediatric Regulation, and similar initiatives across Asia-Pacific are mandating age-appropriate studies as part of new drug applications. This shift has led to a steady increase in pediatric clinical trials across therapeutic areas including oncology, rare genetic disorders, neurology, endocrinology, infectious diseases, and respiratory care. These trials must address complex considerations-age-appropriate dosing, developmental pharmacokinetics, formulation design, ethical consent, and long-term outcome monitoring-that demand specialized protocols and infrastructure. As such, pediatric trial execution has become a niche specialization requiring tailored investigator training, pediatric-focused clinical research organizations (CROs), and the involvement of pediatric patient advocacy groups. Major pharmaceutical companies are establishing dedicated pediatric centers of excellence to integrate child-centric research earlier in the drug development lifecycle. Moreover, with a global rise in early disease detection through newborn screening and genetic testing, clinical trial designs are evolving to accommodate both acute and preventive investigational therapies in pediatric populations. The increasing institutionalization of pediatric research is not just a regulatory requirement-it is a transformative shift toward age-inclusive evidence-based medicine.

How Are Trial Designs and Regulatory Innovations Reshaping the Pediatric Research Model?

Advancements in clinical trial methodologies and regulatory strategies are playing a transformative role in making pediatric research more agile, precise, and ethically sound. Traditional clinical trial models are often ill-suited for pediatric populations due to recruitment challenges, small patient pools, and the ethical sensitivity of involving children in experimental treatments. In response, regulators and sponsors are embracing adaptive trial designs, Bayesian statistics, and real-world evidence (RWE) models to extract meaningful data from smaller, stratified cohorts. Pediatric trials are increasingly incorporating decentralized and hybrid frameworks, leveraging telehealth, wearable sensors, and remote data capture to reduce the burden on participants and their families. These models are proving particularly valuable in rare disease research, where patient populations are geographically dispersed and enrollment must be maximized across borders. Simultaneously, age de-escalation strategies, where trials begin with adolescents and gradually include younger children and infants, are helping mitigate safety risks and refine dosing protocols. On the regulatory front, agencies are offering fast-track designations, pediatric investigation plans (PIPs), and incentives like extended market exclusivity for companies that proactively pursue pediatric indications. Ethics committees are becoming more streamlined and globally harmonized, facilitating faster multi-site trial approvals. Additionally, digital platforms for e-consent and child-friendly trial education materials are helping overcome parental hesitancy and enhance informed participation. These innovations are not merely administrative conveniences-they are enabling more efficient, scalable, and compliant pediatric trials that maintain scientific rigor while respecting the unique needs of children and their caregivers.

Why Are Sponsors and CROs Investing More Aggressively in Pediatric Trial Infrastructure?

The operational landscape of pediatric clinical trials is being reshaped by growing sponsor interest and a surge in pediatric-focused infrastructure development. Clinical research organizations (CROs) are expanding their pediatric portfolios, recruiting child-specific principal investigators, and forming dedicated pediatric project management teams to serve the complex logistical, regulatory, and therapeutic demands of youth-focused trials. Leading sponsors are investing in pediatric research hubs and trial networks within children’s hospitals and academic medical centers, recognizing that high-quality data and enrollment efficiency depend heavily on access to specialized clinical sites. There is also a strong movement toward globalizing pediatric trials, particularly across emerging markets such as India, Brazil, and Southeast Asia, where large pediatric populations and expanding healthcare infrastructure offer untapped potential for recruitment. These expansions are supported by governments and NGOs that are facilitating trial site development and capacity-building initiatives. Moreover, the rise in rare pediatric diseases has catalyzed collaboration between pharmaceutical companies, non-profit foundations, and patient advocacy groups to co-develop trial protocols, natural history databases, and registries. Integration of genomic and biomarker-driven eligibility criteria is also refining patient selection, particularly in oncology and neurology, enabling more targeted and meaningful outcomes. Technological infrastructure, such as electronic data capture (EDC), remote monitoring platforms, and digital patient engagement tools, is enhancing real-time oversight and compliance. Collectively, these efforts are streamlining trial operations, reducing cycle times, and increasing the scalability of pediatric trials. This infrastructure transformation reflects a long-term strategic shift, positioning pediatric trials as a core pillar of future clinical development pipelines rather than a regulatory afterthought.

The Growth in the Pediatric Clinical Trials Market Is Driven by Several Factors…

The growth in the pediatric clinical trials market is driven by several factors anchored in regulatory mandates, therapeutic innovation, and evolving trial execution models. One of the foremost drivers is the increasing regulatory pressure to include pediatric populations in new drug and biologic development programs, prompting sponsors to initiate parallel pediatric plans early in the product lifecycle. Simultaneously, the expansion of precision medicine and gene therapy pipelines targeting pediatric-onset diseases-particularly in oncology, neurology, and rare genetic disorders-is necessitating age-stratified trials with pediatric-specific endpoints. On the end-use front, children’s hospitals, academic pediatric centers, and global research networks are investing in trial-ready infrastructure, including pediatric biobanks, genomic screening tools, and centralized ethics review mechanisms, accelerating trial setup and execution. Advances in pediatric formulation science are another key growth factor, enabling age-appropriate delivery systems such as mini-tablets, dissolvable films, and taste-masked liquids that support trial adherence and safety. Additionally, digital transformation is playing a vital role-remote patient monitoring, decentralized trial platforms, and AI-based patient matching are improving recruitment, retention, and real-time data analysis. From a consumer standpoint, heightened parental awareness, advocacy group activism, and growing public trust in pediatric research are enhancing enrollment rates and trial transparency. There is also increasing alignment between sponsors and healthcare providers to integrate research with routine care, allowing real-world evidence generation within standard pediatric practice. As biopharma companies seek to differentiate their pipelines and fulfill unmet needs in pediatric populations, the clinical trials segment is experiencing an infusion of funding, innovation, and strategic prioritization. These converging dynamics are not only accelerating the pace of pediatric drug development but are also laying the foundation for a more inclusive, data-driven, and child-centric global clinical research ecosystem.

SCOPE OF STUDY:

The report analyzes the Pediatric Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase I, Phase II, Phase III, Phase IV); Study Design (Treatment Studies, Observational Studies); Indication (Infectious Diseases, Oncology, Autoimmune / inflammation, Respiratory Disorders, Mental Health Disorders, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• AbbVie Inc.
• Bristol-Myers Squibb Company
• Charles River Laboratories International Inc.
• Covance Inc. (now part of Labcorp)
• Eli Lilly and Company
• GlaxoSmithKline plc (GSK)
• ICON plc
• IQVIA Holdings Inc.
• Johnson & Johnson
• Medpace, Inc.
• Novartis AG
• Parexel International Corporation
• Pfizer Inc.
• PPD Inc. (Pharmaceutical Product Development)
• PRA Health Sciences (now part of ICON plc)
• Premier Research
• Sanofi S.A.
• Syneos Health Inc.
• Takeda Pharmaceutical Company Limited
• The Emmes Company, LLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Pediatric Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Emphasis on Age-Specific Drug Development Propels Growth in Pediatric Clinical Trials
  • Implementation of Pediatric Investigation Plans in Regulatory Frameworks Strengthens Trial Mandates
  • Global Push for Ethical Pediatric Trial Designs Throws Spotlight on Consent and Safety Innovations
  • Growing Burden of Chronic Pediatric Illnesses Expands Demand for Targeted Therapeutic Studies
  • Public-Private Collaborations Accelerate Launch of Pediatric Rare Disease Trials Globally
  • Expansion of Pediatric Research Networks Enhances Infrastructure for Multi-Center Clinical Trials
  • Rising Regulatory Incentives and Fast-Track Approvals Drive Pediatric Trial Activity
  • Increasing Focus on Formulation Science Spurs Trials for Age-Appropriate Drug Delivery Technologies
  • Advancements in Remote Monitoring Tools Enable Decentralized and Home-Based Pediatric Trials
  • Integration of Real-World Evidence in Trial Designs Strengthens Case for Regulatory Submissions
  • Growth in Pediatric Oncology and Neurology Research Expands Addressable Trial Pipelines
  • Use of AI and Predictive Modeling in Patient Recruitment Optimizes Pediatric Cohort Identification
  • Surge in Orphan Drug Designations Generates Demand for Pediatric Pharmacokinetic and Safety Studies
  • Expansion of Adaptive Trial Methodologies Sustains Flexibility in Pediatric Study Protocols
  • Global Harmonization of Trial Guidelines Improves Regulatory Clarity and Sponsor Confidence
  • Rise in Patient Advocacy Participation Drives Design of Child-Centric and Family-Friendly Trials
  • Digital Therapeutics and Companion Apps Enhance Trial Engagement and Data Collection Accuracy
  • Ethical Imperatives for Equity in Research Access Propel Inclusion of Pediatric Subpopulations
  • Growing Need for Pediatric-Specific Biomarkers and Endpoints Drives Innovation in Trial Methodologies
  • Increased Investment in Pediatric CRO Capabilities Strengthens Global Trial Execution Infrastructure
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pediatric Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Pediatric Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Pediatric Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Respiratory Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Mental Health Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Mental Health Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Mental Health Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Autoimmune / inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Autoimmune / inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Autoimmune / inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Treatment Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Treatment Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Treatment Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Observational Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Observational Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Observational Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• JAPAN
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• CHINA
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• EUROPE
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Pediatric Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Pediatric Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• FRANCE
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• GERMANY
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Pediatric Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Pediatric Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• INDIA
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Pediatric Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Pediatric Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Pediatric Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Pediatric Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030
• AFRICA
  • Pediatric Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Pediatric Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Pediatric Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Pediatric Clinical Trials by Indication - Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Pediatric Clinical Trials by Indication - Percentage Breakdown of Value Sales for Respiratory Disorders, Mental Health Disorders, Others, Infectious Diseases, Oncology and Autoimmune / inflammation for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Pediatric Clinical Trials by Study Design - Treatment Studies and Observational Studies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Pediatric Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Treatment Studies and Observational Studies for the Years 2015, 2025 & 2030

IV. COMPETITION